OSE Immunotherapeutics SA (0RAD) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of OSE Immunotherapeutics SA €0.59, price €2.10, upside -71.9%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €2.10 – €13.65 · fair‑value band €0.3900 – €0.7400 · the €2.10 price screens above the €0.5900 fair value. Dashed = 300-day average. As of Sep 24, 2026.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
Show more
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; ABBV-230, an agonist antibody against ChemR23 to resolve chronic inflammation; and CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a new technology of bispecific checkpoint inhibitors targeting the PD1 receptor and other innovative targets. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Stock analysis
OSE Immunotherapeutics SA (0RAD) currently trades at €2.10, while our model-based Fair Value estimate is €0.5900, 71.9% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
Scenario range: €0.3900 (bear) to €0.7400 (bull), the price of €2.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
OSE Immunotherapeutics SA reported revenue of €10.4M in FY2020 versus €383K in FY2016, a compound +128.5%/yr. Reported net income was −€16.6M in FY2020.
Key figures
Market cap €53.8M · P/S ratio 20.0 · EPS (TTM) €−0.9300 · Return on equity −82.3% · Return on assets (EBIT) −2.3% · Operating margin −2,272% · Revenue growth (YoY) −0.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 71% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −72%, 0RAD screens richer than that median.
Fair Value models
Bear €0.3900Fair Value €0.5900Bull €0.7400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−59.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.0%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4,577.3% (2016) → −182.0% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "OSE Immunotherapeutics SA Fair Value". https://www.fairvalue-calculator.com/stock/0RAD
Frequently asked questions
Is OSE Immunotherapeutics SA (0RAD) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €0.5900 versus a price of €2.10, about −72% upside (overvalued).
What is the fair value of 0RAD?
Our model-based fair value for OSE Immunotherapeutics SA is €0.5900 (as of Sep 24, 2026), built from audited fundamentals. The current price: €2.10.
What is the quality score of 0RAD?
OSE Immunotherapeutics SA has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OSE Immunotherapeutics SA (0RAD)?
Our model-based price target is the fair value of €0.5900 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario €0.3900, optimistic scenario €0.7400. It is a calculation from audited fundamentals, not an analyst target.
What is the OSE Immunotherapeutics SA stock forecast for 2026?
Our models put fair value at €0.5900, about −72% upside versus a price of €2.10 (overvalued). Cautious scenario €0.3900, optimistic scenario €0.7400. The calculation is refreshed regularly with new filings.
What is the intrinsic value of OSE Immunotherapeutics SA (0RAD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OSE Immunotherapeutics SA it is €0.5900 per share (as of Sep 24, 2026), against a price of €2.10. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is OSE Immunotherapeutics SA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0RAD trades above its calculated fair value: price €2.10, fair value €0.5900, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RAD?
No. The price is what the market pays today (€2.10); the fair value is what the company's own numbers justify (€0.5900). For OSE Immunotherapeutics SA the two are €1.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is OSE Immunotherapeutics SA worth?
The market values OSE Immunotherapeutics SA at about €53.8M (market capitalisation, as of Sep 24, 2026). Per share that is €2.10; our models calculate a fair value of €0.5900 per share.
What do the bullish and bearish scenarios say about 0RAD?
Our models span a range for OSE Immunotherapeutics SA: cautious scenario €0.3900, base €0.5900, optimistic €0.7400 per share (as of Sep 24, 2026, price €2.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0RAD from its 52-week high?
OSE Immunotherapeutics SA trades at €2.10, about 71% below its 52-week high of €7.11 and at the low of €2.10 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €0.5900 is for.
Which stocks are comparable to OSE Immunotherapeutics SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OSE Immunotherapeutics SA stock attractive at the current price?
The data as of Sep 24, 2026: price €2.10, calculated fair value €0.5900 (−72%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RAD calculated?
We run OSE Immunotherapeutics SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.5900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. OSE Immunotherapeutics SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OSE Immunotherapeutics SA (0RAD)?
The closing price on Oct 2, 2026 was €2.10. Our model-based fair value is €0.5900, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OSE Immunotherapeutics SA right now?
The price sits above even our optimistic bull case (€0.7400). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.3900 to €0.7400) leaves room in how you read the outcome.
Key figures of OSE Immunotherapeutics SA
How large is the market capitalisation of OSE Immunotherapeutics SA (0RAD)?
The market capitalisation of OSE Immunotherapeutics SA is €53.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OSE Immunotherapeutics SA (0RAD)?
The price-to-sales ratio of OSE Immunotherapeutics SA is 20.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OSE Immunotherapeutics SA (0RAD)?
Earnings per share at OSE Immunotherapeutics SA are €−0.9300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of OSE Immunotherapeutics SA (0RAD)?
The return on equity (ROE) of OSE Immunotherapeutics SA is −82.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OSE Immunotherapeutics SA (0RAD)?
On an EBIT basis the return on assets of OSE Immunotherapeutics SA is −2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OSE Immunotherapeutics SA (0RAD)?
The operating margin of OSE Immunotherapeutics SA is −2,272% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OSE Immunotherapeutics SA (0RAD)?
Revenue at OSE Immunotherapeutics SA is growing −0.8% versus a year earlier (3y avg +16.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
